What are you searching for?

Sign in
Breaking News

Lilly Completes $34.6M Acquisition of Sigilon Therapeutics

Lilly to continue development of encapsulated cell therapies, including SIG-002 for the treatment of type 1 diabetes.

Lilly has completed the acquisition of Sigilon Therapeutics, Inc., a biopharmaceutical company working to develop functional cures for a broad range of acute and chronic diseases, for approximately $34.6 million.
 
Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The goal of these therapies is to free patients from constant disease management by sensing blood glucose levels, restoring insulin production and releasing it over the long term.
 
The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.

“Make life better – that’s the phrase that guides everything we do at Lilly,” said Ruth Gimeno, group vice president, diabetes, obesity and cardiometabolic research at Lilly. “We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of constant disease management, and advance Sigilon’s technology for patients.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics